249 related articles for article (PubMed ID: 31981081)
1. Hyperkeratotic Skin Adverse Events Induced by Anticancer Treatments: A Comprehensive Review.
Vastarella M; Fabbrocini G; Sibaud V
Drug Saf; 2020 May; 43(5):395-408. PubMed ID: 31981081
[TBL] [Abstract][Full Text] [Related]
2. Pityriasis rubra pilaris-like erythroderma secondary to phosphoinositide 3-kinase inhibition.
Dewan AK; Sowerby L; Jadeja S; Lian C; Wen P; Brown JR; Fisher DC; LeBoeuf NR
Clin Exp Dermatol; 2018 Dec; 43(8):890-894. PubMed ID: 29851132
[TBL] [Abstract][Full Text] [Related]
3. Pityriasis Rubra Pilaris-Like Reaction Induced by a Tyrosine Kinase Inhibitor, the Ponatinib.
Mongereau M; Hillion B; Fouillard L; Boivin JF; Gaudron S
Am J Dermatopathol; 2021 May; 43(5):394-395. PubMed ID: 33264130
[No Abstract] [Full Text] [Related]
4. Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review.
Leite OG; Tagliolatto S; Souza EM; Cintra ML
An Bras Dermatol; 2020; 95(1):63-66. PubMed ID: 31789270
[TBL] [Abstract][Full Text] [Related]
5. Follicular Psoriasis: Differentiation from Pityriasis Rubra Pilaris-An Illustrative Case and Review of the Literature.
Nguyen CV; Farah RS; Maguiness SM; Miller DD
Pediatr Dermatol; 2017 Jan; 34(1):e65-e68. PubMed ID: 27874201
[TBL] [Abstract][Full Text] [Related]
6. Circumscribed Juvenile Pityriasis Rubra Pilaris (Type 4) Koebnerising after a Hot Water Burn: Mild Disease with Maximum Koebner Response.
Acar EM; Has S; Kilitci A; Kemeriz F
Acta Dermatovenerol Croat; 2019 Mar; 27(1):47-49. PubMed ID: 31032794
[TBL] [Abstract][Full Text] [Related]
7. Pityriasis rubra pilaris-like reaction induced by imatinib.
Plana A; Carrascosa JM; Vilavella M; Ferrandiz C
Clin Exp Dermatol; 2013 Jul; 38(5):520-2. PubMed ID: 23777493
[TBL] [Abstract][Full Text] [Related]
8. Pityriasis rubra pilaris exacerbation with topical use of imiquimod.
Yang FC; Jessup C; Dahiya M; Reynolds R
Int J Dermatol; 2008 Oct; 47(10):1076-8. PubMed ID: 18986361
[TBL] [Abstract][Full Text] [Related]
9. Ponatinib-induced atypical pityriasis rubra pilaris-like rash.
Kamat D; Chatterjee D; Mahajan R
Indian J Dermatol Venereol Leprol; 2020; 86(6):688-690. PubMed ID: 33159027
[No Abstract] [Full Text] [Related]
10. Methotrexate treatment in a case of juvenile pityriasis rubra pilaris.
Boyd AH; Polcari IC
Pediatr Dermatol; 2018 Jan; 35(1):e62-e63. PubMed ID: 29044698
[TBL] [Abstract][Full Text] [Related]
11. Ponatinib-Associated Cutaneous Eruptions-A Case Series and Review of Clinicopathologic Findings.
Weber I; Gloss C; Castillo B; Smith E
Am J Dermatopathol; 2023 Jan; 45(1):64-68. PubMed ID: 36484611
[TBL] [Abstract][Full Text] [Related]
12. [A new case of pityriasis rubra pilaris-like eruption associated with ponatinib, a tyrosine kinase inhibitor].
Krygier J; Leemans G; Forsyth R; de Becker A; Gutermuth J; Grosber M
Ann Dermatol Venereol; 2018 Nov; 145(11):665-670. PubMed ID: 29903676
[TBL] [Abstract][Full Text] [Related]
13. [Pityriasis rubra pilaris after COVID-19 vaccination: causal relationship or coincidence?].
Bramhoff AC; Wesselmann U; Bender ST; Berghoff AV; Hofmann SC; Balakirski G
Dermatologie (Heidelb); 2022 Aug; 73(8):634-637. PubMed ID: 35296923
[TBL] [Abstract][Full Text] [Related]
14. Case for diagnosis. Atypical Grover's disease.
Vargas-Mora P; Orlandi D; Araya I; Morales C
An Bras Dermatol; 2021; 96(2):234-236. PubMed ID: 33589293
[TBL] [Abstract][Full Text] [Related]
15. Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report.
Saad M; Spurr A; Lipson J
SAGE Open Med Case Rep; 2023; 11():2050313X231160927. PubMed ID: 37009550
[TBL] [Abstract][Full Text] [Related]
16. Surgical Management of Cicatricial Ectropion in Pityriasis Rubra Pilaris.
Haridas AS; Sullivan TJ
Ophthalmic Plast Reconstr Surg; 2016; 32(1):e12-5. PubMed ID: 25794020
[TBL] [Abstract][Full Text] [Related]
17. Dermatomyositis with a pityriasis rubra pilaris-like eruption: an uncommon cutaneous manifestation in dermatomyositis.
Polat M; Lenk N; Ustün H; Oztaş P; Artüz F; Alli N
Pediatr Dermatol; 2007; 24(2):151-4. PubMed ID: 17461814
[TBL] [Abstract][Full Text] [Related]
18. Exacerbation of pityriasis rubra pilaris under efalizumab therapy.
Klein A; Szeimies RM; Landthaler M; Karrer S
Dermatology; 2007; 215(1):72-5. PubMed ID: 17587845
[TBL] [Abstract][Full Text] [Related]
19. Pityriasis rubra pilaris-like eruption associated with the multikinase inhibitor ponatinib.
Jack A; Mauro MJ; Ehst BD
J Am Acad Dermatol; 2013 Nov; 69(5):e249-e250. PubMed ID: 24124847
[No Abstract] [Full Text] [Related]
20. Toxic doses of vitamin A for pityriasis rubra pilaris.
Randle HW; Diaz-Perez JL; Winkelmann RK
Arch Dermatol; 1980 Aug; 116(8):888-92. PubMed ID: 7406516
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
